Combination glaucoma drop moves toward approval

Article

A preservative-free IOP-lowering eye drop that is a combination of tafluprost and timolol (Taptiqom, Santen) is seeking national licences in European countries after a positive decentralized procedure and a final assessment report from reference member state Germany, the Federal Institute for Drugs and Medical Devices of Germany, and agreement by concerned member states that the fixed-dose product is approvable.

A preservative-free IOP-lowering eye drop that is a combination of tafluprost and timolol (Taptiqom, Santen) is seeking national licences in European countries after a positive decentralized procedure and a final assessment report from reference member state Germany, the Federal Institute for Drugs and Medical Devices of Germany, and agreement by concerned member states that the fixed-dose product is approvable.

The drug, co-developed by Santen and Asahi Glass Co., comes in single-dose containers with 15 µg/mL of the prostaglandin tafluprost and 5 mg/mL of the beta blocker timolol. These two components lower IOP by complementary mechanisms of action, according to Santen, and the combined effect results in additional IOP reduction compared with either compound alone. The drop will be indicated for the reduction of IOP in adults who have open-angle glaucoma or ocular hypertension that has been insufficiently responsive to topical monotherapy.

Santen said it will work to make the drug available as soon as possible. For more detailed information on this news click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.